I think this is so provocative yet seldom talked about.
The "magic" may truly be an abscopal effect. That is to say, as counterintuitive as it seems, irradiating just a percent of the subclinical/microscopic disease in a breast cancer patient's body may illicit a response in the unirradiated cells.
And this explains why we will never see OS benefits from RNI machinations or differing styles thereof in most breast cancers. Locoregional therapy can be too sloppy and hurt survival, but it can be as fancy as you'd like and the returns rapidly diminish. Again confirming
Fisher:
This trial had an enormous influence on how radiation oncologistssurgeons and clinicians perceived the behavior of breast cancer; it convinced them, once and for all, that nuances in locoregional therapy were unlikely to have a substantial influence on ultimate survival and that patients succumbed to the disease not because of inattention to radiotherapeuticoperative detail but rather because micrometastases were present at the time of the initial irradiationoperation. This provided the biologic rationale for the evolution of clinical trials that evaluated not only additional reduction in the extent of locoregional therapy, but also, more importantly, the use of adjuvant systemic therapy.